Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease
Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease
复制标题
DOI：
10.1016/j.amjcard.2007.01.069
复制
发表时间：
2007-07-01
影响因子：
2.8
通讯作者：
Slimane, Mohamed Naceur
中科院分区：
文献类型：
--
作者：
Jguirim-Souissi, Imen;Jelassi, Awatef;Slimane, Mohamed Naceur
几种基质金属蛋白酶（MMPs）和金属蛋白酶组织抑制剂（TIMPs）与冠状动脉疾病（CAD）的发生和转归有关。我们研究了MMP-12和TIMP-1水平是否与CAD的风险、严重程度和结局相关。采用酶联免疫吸附法测定了50例和44例冠心病患者血浆MMP-12和TIMP-Ⅰ水平。在所有患者中，16人正在服用他汀类药物。未使用他汀类药物的患者根据> 50%狭窄血管的数量分为3组。与29名无CAD的志愿者相比，未使用他汀类药物的患者（n = 34）的MMP-12浓度更高（1.71 vs 1.08 ng/ml，p = 0.021）。MMP-12水平在接受他汀类药物治疗的患者中显著低于未接受他汀类药物治疗的患者（0.99 vs 1.71 ng/ml，p = 0.008）。MMP-12水平与>50%狭窄血管的数量之间无相关性。MMP-12浓度与CAD的结局无关。然而，血浆TIMP-1水平与再狭窄相关，与狭窄血管数量和年龄无关（p = 0.035），但与CAD的风险或严重程度无关。总之，血浆MMP-12浓度与CAD的存在相关。他汀类药物治疗降低CAD患者血浆MMP-12水平TIMP-1水平升高可预防血管成形术后再狭窄。(C)2007爱思唯尔公司All rights reserved.
Several matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been implicated in the development and outcome of coronary artery disease (CAD). We investigated whether MMP-12 and TIMP-1 levels were associated with risk, severity, and outcome of CAD. Plasma MMP-12 and TIMP- I levels are measured in 50 and 44 patients with CAD, respectively, by enzyme-linked immunosorbent assay. Of all patients, 16 were taking statins. Patients who were not on statins were classified into 3 groups according to number of > 50% stenotic vessels. Compared with 29 volunteers without CAD, patients without statins (n = 34) had higher MMP-12 concentrations (1.71 vs 1.08 ng/ml, p = 0.021). MMP-12 levels were significantly lower in patients with than in those without statin treatment (0.99 vs 1.71 ng/ml, p = 0.008). There was no association between MMP-12 levels and number of >50% stenotic vessels. MMP-12 concentrations were not associated with outcome of CAD. However, plasma TIMP-1 levels were associated with restenosis independently of number of stenotic vessels and age (p = 0.035) but not with risk or severity of CAD. In conclusion, plasma MMP-12 concentration was associated with the presence of CAD. Statin therapy decreases plasma MMP-12 levels in patients with CAD. Increased TIMP-1 levels may prevent restenosis after angioplasty. (C) 2007 Elsevier Inc. All rights reserved.